About Marengo
Marengo is a company based in Cambridge (United States) founded in 2015. Marengo has raised $80 million across 1 funding round from investors including Apple Tree Partners. Marengo offers products and services including TCR-targeting Antibodies. Marengo operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website marengotx.com
- Social LinkedIn X
- Legal Name Marengo Therapeutics, Inc.
- Total Equity Funding$80M (USD)
in 1 rounds
- Latest Funding Round$80M (USD), Series C
Nov 2021
- Investors
Products & Services of Marengo
Marengo offers a comprehensive portfolio of products and services, including TCR-targeting Antibodies.
Antibodies that modulate T cells to fight cancer and diseases.
Funding Insights of Marengo
Marengo has successfully raised a total of $80M through 1 strategic funding round. The most recent funding activity was a Series C round of $80 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80M
- Total Rounds 1
- Last Round Series C β $80M
- First Round $80M
(Nov 2021)
- Investors Count 1
All 1 funding rounds of Marengo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $80M | Series C | β | Apple Tree Partners | β |
1 investors in total: 1 institutional.
Investors in Marengo
Marengo has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Apple Tree Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Apple Tree Partners is engaged in life sciences venture capital. | – | appletreepartners.com | - |
Investor details for Marengo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Marengo
38 people are tracked at Marengo (18 in leadership, 11 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Zhen Su | CEO | Leadership |
Sharon Cross, PharmD | Associate Director Of Clinical Operations | Leadership |
Kevin Chin | Chief Medical Officer | Leadership |
Ke Liu | Chief Development Officer | Leadership |
Svetlana Makhni | Chief Financial Officer | Leadership |
Svetlana Ni Makhni | Chief Financial Officer | Leadership |
Ryan Bird | Senior Director, CMC | Leadership |
Shiva Bolourchi | Senior Director, Corporate Development & Strategy | Leadership |
Madan Katragadda | VP & Head of Discovery | Leadership |
Christopher Leahy, CPA | Executive Director, Finance And Corporate Controller | Leadership |
Gurkan Guntas | Director | Leadership |
Jonathan Hsu | Scientific Director - Immunology | Leadership |
Karunya Srinivasan | Director | Leadership |
Katie Niland | Vice President, Clinical Development Operations | Leadership |
Madan Katragadda Ph.D., MBA | Vp, Head Of Antibody Technologies And CMC | Leadership |
Elena Geretti | Senior Director, Immunology | Leadership |
J.d. Schonhoft | Associate Director, Precision Immunotherapy, Cdx | Leadership |
Ke Liu , MD, PhD | Chief Development Officer at Marengo Therapeutics | Leadership |
Joseph A. Yanchik III | Board Member | Board & advisors |
Anna Batarina | Board Member | Board & advisors |
18 more people are available in the full profile.
Complete people profiles for Marengo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Marengo
2 dated milestones of Marengo across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Marengo is founded.
- Funding First funding round of $80.0M.
Competitors of Marengo
Marengo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Marengo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Marengo
The website of Marengo (marengotx.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▼ 36.4% vs previous month
Websites whose visitors overlap most with Marengo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| prometrika.com | 100% | – | #2,751,954 | View details | |
| cugene.com | 99% | 1.1K | #13,064,449 | View details | |
| oxeiabiopharma.com | 98% | 3.3K | #5,389,668 | View details | |
| vedantabio.com | 98% | 5.6K | #3,168,764 | View details | |
| hcbioscience.com | 98% | – | – | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 11 similar websites and full traffic analytics for Marengo
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Marengo
Complete news archive for Marengo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Marengo
10 companies that operate in the same segment as Marengo (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Marengo
Marengo was founded in 2015 and raised its 1st funding round 6 years after it was founded.
Marengo is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Zhen Su is the current CEO of Marengo.
Marengo is a funded company, having raised a total of $80M across 1 funding round to date. The company's 1st funding round was a Series C of $80M, raised on Nov 2021.
Marengo was founded in 2015 and is based in Cambridge, United States. Operations center on the biotechnology sector, where cell therapies for cancer are developed. The lead program, STAR0602, is structured as an antibody fusion molecule that binds specific T cells via VΞ² TCR variants to support anti-tumor responses. Other initiatives, such as STAR0615, STAR2002, SKAR3012, and STAR0602X, target solid tumors.
Marengo's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Marengo offers TCR-targeting Antibodies.
Marengo has 1 investor. Key investors include Apple Tree Partners.
Marengo operates through Marengo Therapeutics, Inc..